甲蓝色注碳化聚合物点:一种强大的光氧化清除剂,向阿尔茨海默氏症的β-粉样蛋白
Xiaoding Lin1, Hui Zhang1, Wei Liu2
1Department of Biochemical Engineering, School of Chemical Engineering and Technology and Key Laboratory of Systems Bioengineering and Frontiers Science Center for Synthetic Biology (Ministry of Education), Tianjin University, Tianjin 300350, China.
ACS applied materials & interfaces
|September 8, 2023
概括
研究人员开发了一种新型的甲蓝化碳化聚合物点 (MB-CPDs),可以有效地抑制阿尔茨海默病 (AD) 模型中的β-粉样蛋白 (Aβ) 聚合. 这些纳米材料通过减少有毒的蛋白质块和改善细胞和生物的生存,对阿尔茨海默病的治疗具有前景.
科学领域:
- 纳米材料科学 科学 纳米材料科学
- 生物化学 生化学
- 神经科学是一个神经科学.
背景情况:
- β-粉样蛋白 (Aβ) 的异常聚合是阿尔茨海默病 (AD) 的关键病理特征.
- 开发有效的Aβ除尘器是AD治疗的关键策略.
- 碳化聚合物点 (CPD) 具有生物医学应用的潜力.
研究的目的:
- 合成带有光敏感剂的碳化聚合物点 (PS-CPDs),以抑制Aβ聚合.
- 为了研究甲蓝合碳化聚合物点 (MB-CPDs) 在分解Aβ纤维的有效性.
- 在AD的细胞和线虫模型中评估MB-CPDs的治疗潜力.
主要方法:
- 使用光敏感剂和o-phenylenediamine的PS-CPDs的一步热水合成.
- 在650nm近红外光照射下使用MB-CPD抑制Aβ纤维的Aβ聚合和分离.
- 在AD线虫模型中评估细胞活力和寿命延长.
主要成果:
- MB-CPDs通过光氧化证明了Aβ纤维化和成熟Aβ纤维的分解的强烈抑制.
- 在辐射下,MB-CPD显著提高了培养细胞的活力,从50%提高到83%.
- 在体内研究表明,MB-CPDs可将AD线虫的寿命延长4天.
- 与甲基蓝和之前报告的CPD相比,MB-CPDs表现出更高的抑制能力.
结论:
- 用光敏感剂添加的碳点可以有效地被设计为强大的光氧化剂.
- 在阿尔茨海默病治疗中,MB-CPDs代表了针对Aβ的有希望的纳米材料.
- 这项研究为设计用于AD治疗的碳纳米材料提供了新的见解.
相关概念视频
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
Alzheimer's Disease: Overview
517
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
517


